

Specialty pharmacy prior authorization update — drugs for treatment of ocular conditions

Summary of change: In a recent provider bulletin, we advised we would no longer require prior authorization (PA) for the following drugs used to treat ocular conditions, effective May 1, 2021. **Please be advised that PA will continue to be required for these drugs.** We apologize for any inconvenience.

Drug	Code	Code description
*Avastin	J9035	intravitreal bevacizumab
*Mvasi	Q5107	bevacizumab-awwb
*Zirabev	Q5118	bevacizumab-bvzr

* Our specialty drug review team manages non-oncology use.